BiomarkersFDA Approvals, News & Updates

Tabrecta Approved for NSCLC with MET Biomarker

On May 6, 2020, the FDA approved Tabrecta (capmatinib; from Novartis), an oral kinase inhibitor, for adults with metastatic (spreading) non–small-cell lung cancer (NSCLC).

June 2020 Vol 6 No 3

On May 6, 2020, the FDA approved Tabrecta (capmatinib; from Novartis), an oral kinase inhibitor, for adults with metastatic (spreading) non–small-cell lung cancer (NSCLC).

To be able to receive Tabrecta, patients must be tested to identify this biomarker (or mutation). Therefore, on the same day, the FDA also approved the Foundation

One CDx assay as a diagnostic test for Tabrecta.

“Tabrecta is the first approval specifically for the treatment of patients with non–small-cell lung cancer whose tumors have mutations that lead to MET exon 14 skipping. This patient population now has an option for a targeted therapy,” said Richard Pazdur, M.D., Director of the FDA’s Oncology Center of Excellence.

The clinical trial that led to the approval of Tabrecta included patients with NSCLC and the MET biomarker; patients were not included if they had EGFR or ALK gene mutations.

Among the 28 patients who had never received treatment for NSCLC, the overall response was 68%, including 4% complete responses and 64% partial responses. Among the 69 patients who received previous therapy, 41% had a partial response to Tabrecta. Moreover, 47% of the patients who received Tabrecta as first treatment versus 32.1% of patients who had previously received other NSCLC therapy responded to Tabrecta.

The most common side effects with Tabrecta were rash, nausea, fatigue, vomiting, shortness of breath, and reduced appetite. The serious side effects included interstitial lung disease or pneumonitis.

Recommended For You
BiomarkersBreast CancerSurvivorship
Surviving Pregnancy and Breast Cancer
By Kelsey Moroz
With her family history of cancers related to the BRCA mutation, Jamie Ledezma’s first pregnancy suddenly got very complicated when she learned she had triple-negative breast cancer.
Breast CancerFDA Approvals, News & Updates
Trodelvy New Therapy Approved for Triple-Negative Breast Cancer
In April, 2020, the FDA approved Trodelvy for the treatment of adults with metastatic triple-negative breast cancer after 2 or more previous therapies.
FDA Approvals, News & UpdatesLeukemia
First-Line Treatment with Calquence Produces Long-Term Responses in Patients with Chronic Lymphocytic Leukemia
By Dana Taylor
The FDA approved a new Bruton tyrosine kinase (or BTK), Calquence, for first-line treatment of patients with CLL.
FDA Approvals, News & UpdatesOvarian Cancer
Zejula Now Approved as First-Line Maintenance Therapy in All Patients with Ovarian Cancer
In April 2020, the FDA approved Zejula for long-term maintenance therapy for all patients with advanced ovarian cancer, regardless of any gene mutations.
Last modified: June 24, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.